180 Life Sciences Corp.
For the period ended Jun 30, 2025. Filed Jul 23, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 23, 2025
FRMM$2.82-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Expressed in US Dollars)
| For the Six Months Ended June 30, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| Cash Flows From Operating Activities | ||||
| Net loss | $(4,095,836) | $(1,057,963) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Shares issued for services | 676,456 | - | ||
| Amortization of stock options and restricted stock units | 4,752 | 258,370 | ||
| Amortization of intangibles | - | 47,557 | ||
| Change in fair value of derivative liabilities | - | (58) | ||
| Gain on settlement of liabilities | - | (156,928) | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other current assets | 408,440 | 1,236,580 | ||
| Accounts payable | (17,007) | 654,156 | ||
| Accounts payable – related parties | 409,251 | (679,407) | ||
| Accrued expenses | 629,157 | (716,069) | ||
| Accrued expenses – related parties | - | 107,515 | ||
| Total adjustments | 2,111,049 | 751,716 | ||
| Net Cash Used In Operating Activities | (1,984,787) | (306,247) | ||
| Cash Flows From Financing Activities | ||||
| Proceeds from exercise of pre-funded warrants from the Amendment to August 2023 Offering | - | 489 | ||
| Repayment of loans payable | (3,320) | (529,791) | ||
| Repayment of loans payable related parties | (350,000) | - | ||
| Net Cash Used In Financing Activities | (353,320) | (529,302) | ||
| Effect of Exchange Rate Changes on Cash | (28,703) | 6,038 | ||
| Net Decrease In Cash | (2,366,810) | (829,511) | ||
| Cash - Beginning of Period | 4,585,141 | 1,975,799 | ||
| Cash - End of Period | $2,218,331 | $1,146,288 | ||
| Supplemental Disclosures of Cash Flow Information: | ||||
| Cash paid during the period for income taxes | $ | - | $ | - |
| Cash paid during the period for interest | $ | - | $12,078 | |
| Non cash investing and financing activities: | ||||
| Conversion of Series B Convertible Preferred Stock | $100 | $ | - | |
| Shares issued for settlement of liabilities | $751,406 | $523,251 | ||
| Prepaid expense financed with notes payable | $722,000 | $ | - | |
| Commitment to repurchase common stock | $1,000,000 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.